WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) is a clinical-stage pharmaceutical company, with to focus on glioblastoma cancer ("GBM") and other brain tumour programs.
WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. The Company owns approximately 20% of the outstanding shares of WPD Poland.
With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.